BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 31432723)

  • 1. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 2. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
    Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
    J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29-34 wGA) infants without outpatient palivizumab administration.
    Packnett ER; Winer IH; Oladapo A; Wojdyla M
    Hum Vaccin Immunother; 2023 Aug; 19(2):2252289. PubMed ID: 37828711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory Syncytial Virus Burden and Healthcare Utilization in United States Infants <1 Year of Age: Study of Nationally Representative Databases, 2011-2019.
    Suh M; Movva N; Jiang X; Reichert H; Bylsma LC; Fryzek JP; Nelson CB
    J Infect Dis; 2022 Aug; 226(Suppl 2):S184-S194. PubMed ID: 35968879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020.
    Packnett ER; Winer IH; Larkin H; Oladapo A; Gonzales T; Wojdyla M; Goldstein M; Smith VC
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140533. PubMed ID: 36412253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
    Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
    Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
    Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
    J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012-2016.
    Goldstein M; Krilov LR; Fergie J; McLaurin KK; Wade SW; Diakun D; Lenhart GM; Bloomfield A; Kong AM
    Am J Perinatol; 2018 Dec; 35(14):1433-1442. PubMed ID: 29920638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory Syncytial Virus and All-Cause Bronchiolitis Hospitalizations Among Preterm Infants Using the Pediatric Health Information System (PHIS).
    Fergie J; Suh M; Jiang X; Fryzek JP; Gonzales T
    J Infect Dis; 2022 Apr; 225(7):1197-1204. PubMed ID: 32691037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
    Krilov LR; Fergie J; Goldstein M; Brannman L
    Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
    Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study.
    Fryzek JP; Martone WJ; Groothuis JR
    Adv Ther; 2011 Mar; 28(3):195-201. PubMed ID: 21327753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation.
    Goldstein M; Krilov LR; Fergie J; Brannman L; Wade SW; Kong AM; Ambrose CS
    Am J Perinatol; 2021 Aug; 38(S 01):e201-e206. PubMed ID: 32299107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
    Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan.
    Chi H; Chung CH; Lin YJ; Lin CH
    PLoS One; 2018; 13(5):e0197410. PubMed ID: 29746578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Systematic Literature Review of the Burden of Respiratory Syncytial Virus and Health Care Utilization Among United States Infants Younger Than 1 Year.
    Suh M; Movva N; Bylsma LC; Fryzek JP; Nelson CB
    J Infect Dis; 2022 Aug; 226(Suppl 2):S195-S212. PubMed ID: 35968876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
    Anderson EJ; Krilov LR; DeVincenzo JP; Checchia PA; Halasa N; Simões EA; Domachowske JB; Forbes ML; Pannaraj PS; McBride SJ; McLaurin KK; Kumar VR; Ambrose CS
    Am J Perinatol; 2017 Jan; 34(1):51-61. PubMed ID: 27233106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.